Professional Documents
Culture Documents
Textbook Ebook Clinical Pharmacology 12Th Edition Edition Morris J Brown All Chapter PDF
Textbook Ebook Clinical Pharmacology 12Th Edition Edition Morris J Brown All Chapter PDF
Student Consult eBooks give you the power to browse and find content,
view enhanced images, share notes and highlights—both online and offline.
4 Click “Redeem”
5 Log in or Sign up
6 Go to “My Library”
Place Peel Off
It’s that easy! Sticker Here
Use of the current edition of the electronic version of this book (eBook) is subject to the terms of the nontransferable, limited license granted on
studentconsult.inkling.com. Access to the eBook is limited to the first individual who redeems the PIN, located on the inside cover of this book, at studentconsult.inkling.com
and may not be transferred to another party by resale, lending, or other means.
2015v1.0
Clinical Pharmacology
And I will use regimens for the benefit of the ill in accordance with my ability and my judgement.
The Hippocratic Oath c.400 BC
But doctors are lucky: the sun shines on their successes and the earth hides their failures.
Michael de Montaigne 1533–1592
Morals do not forbid making experiments on one’s neighbour or on one’s self … among the experiments that may be
tried on man, those that can only harm are forbidden, those that are innocent are permissible, and those that may
do good are obligatory.
Claude Bernard 1813–1878
It may seem a strange principle to enunciate as the very first requirement in a Hospital that it should do the sick no
harm.
Florence Nightingale 1820–1910
The ingenuity of man has ever been fond of exerting itself to varied forms and combinations of medicines.
William Withering 1741–1799
A desire to take medicine is, perhaps, the great feature which distinguishes man from other animals.
William Osler 1849–1920
All things are poisons and there is nothing that is harmless, the dose alone decides that something is no poison.
Paracelsus 1493–1541
Medical science aims at the truth and nothing but the truth.
William J Mayo 1861–1939
What we find in books is like the fire in our hearths. We fetch it from our neighbors, we kindle it at home, we
communicate it to others, and it becomes the property of all.
Voltaire 1694–1778
Clinical
Pharmacology
Twelfth edition
Morris J. Brown
MA MSc FRCP FAHA FBPharmacolS FMedSci
Professor of Endocrine Hypertension, William Harvey Research Institute of the Barts and the London
School of Medicine and Dentistry, London, UK
Pankaj Sharma
MD PhD FRCP
Professor of Neurology and Director, Institute of Cardiovascular Research, Royal Holloway College,
University of London; and Consultant Neurologist, Imperial College Healthcare NHS Trust, London, UK
Fraz A. Mir
MA, FRCP
Consultant Clinical Pharmacologist, Division of Experimental Medicine and Immunotherapeutics,
Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
Peter N. Bennett
MD FRCP
Formerly Reader in Clinical Pharmacology, University of Bath; and Consultant Physician, Royal United
Hospital, Bath, UK
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical,
including photocopying, recording, or any information storage and retrieval system, without permission in writing from
the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our
arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be
found at our website: www.elsevier.com/permissions.
This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as
may be noted herein).
Notices
Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any
information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences,
in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no
responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or
property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods,
products, instructions, or ideas contained in the material herein.
ISBN: 978-0-7020-7328-1
IE: 978-0-7020-7329-8
Printed in China
Last digit is the print number: 9 8 7 6 5 4 3 2 1
The
publisher’s
policy is to use
paper manufactured
from sustainable forests
Contents
Section 1: General
Section 3: Infection and
inflammation
1 Clinical pharmacology ....................................2
Mike Schachter
12 Chemotherapy of infections ..................... 166
2 Topics in drug therapy ....................................5
David A. Enoch, Mark Farrington
Mike Schachter
13 Antibacterial drugs ...................................... 178
3 Discovery and development of
David A. Enoch, Mark Farrington
drugs ................................................................28
14 Chemotherapy of bacterial infections ..... 198
Patrick Vallance
David A. Enoch, Mark Farrington,
4 Evaluation of drugs in humans ...................37
Surender K. Sharma
Ian Hudson, June Raine
15 Viral, fungal, protozoal and helminthic
5 Health technology assessment .....................56
infections .......................................................221
Michael Rawlins
Sani Aliyu
6 Regulation of medicines ...............................63
16 Drugs for inflammation and joint
Ian Hudson, Keith MacDonald, June Raine
disease ........................................................... 248
7 Classification and naming of drugs ............ 71
Clare Thornton, Justin C. Mason
Morris J. Brown
17 Drugs and the skin ..................................... 269
Thomas K. K. Ha
Section 2: From pharmacology
to toxicology Section 4: Nervous system
v
Contents
vi
Preface
For your own satisfaction and for mine, please read this preface!1
A preface should tell the prospective reader about the subject of a book, its purpose and its plan.
This book is about the scientific basis and practice of drug therapy. It addresses medical students
and doctors in particular, but also anyone concerned with evidence-based drug therapy and
prescribing.
The scope and rate of drug innovation increase. Doctors now face a professional lifetime of
handling drugs that are new to themselves – drugs that do new things as well as drugs that do old
things better – and drugs that were familiar during medical training become redundant.
We write not only for readers who, like us, have a special interest in pharmacology. We try to
make pharmacology understandable for those whose primary interests lie elsewhere but who recognise
that they need some knowledge of pharmacology if they are to meet their moral and legal ‘duty of
care’ to their patients. We are aware, too, of medical curricular pressures that would reduce the time
devoted to teaching clinical pharmacology and therapeutics, and such diminution is surely a misguided
policy for a subject that is so integral to the successful practice of medicine. Thus, we try to tell
readers what they need to know without burdening them with irrelevant information, and we try
to make the subject interesting. We are very serious, but seriousness does not always demand wearying
solemnity.
All who prescribe drugs would be wise to keep in mind the changing and ever more exacting
expectations of patients and of society in general. Doctors who prescribe casually or ignorantly now
face not only increasing criticism but also civil (or even criminal) legal charges. The ability to handle
new developments depends, now more than ever, on comprehension of the principles of pharmacology.
These principles are not difficult to grasp and are not so many as to defeat even the busiest doctors
who take upon themselves the responsibility of introducing manufactured medicines into the bodies
of their patients. The exercise of prescribing calls for the meticulous selection of medicines and so
the avoidance of polypharmacy, which now seems rampant.
The principles of pharmacology and drug therapy appear in Chapters 1–11 and their application
in the subsequent specialist chapters, where we draw on the knowledge and authority of a range of
experts, to whom we express our gratitude. The names of those who contributed to the present and
previous editions appear on subsequent pages.
We seek to offer a reasonably brief solution to the problem of combining practical clinical utility
with an account of the principles on which clinical practice rests.
The quantity of practical technical detail to include is a matter of judgment. In general, where
therapeutic practices are complex, potentially dangerous or commonly updated, e.g. anaphylactic
shock, we provide more detail, together with websites for the latest advice; we give less or even no
detail on therapy that specialists undertake, e.g. anticancer drugs. Nevertheless, especially with modern
drugs that are unfamiliar, prescribers should consult formularies, approved guidelines or the manu-
facturer’s current literature, relevant to their country of practice.
1
St Francis of Sales: Preface to Introduction to the devout life (1609).
vii
Preface
Use of the book. Francis Bacon2 wrote that ‘Some books are to be tasted, others to be swallowed,
and some few to be chewed and digested.’ Perhaps elements of each activity can apply to parts of
our text. Students and doctors are, or should be, concerned to understand and to develop a rational,
critical attitude to drug therapy, and they should therefore chiefly address issues of how drugs act
and interact in disease and how evidence of therapeutic effect is obtained and evaluated.
To this end, they should read selectively and should not impede themselves by attempts to
memorise lists of alternative drugs and doses and minor differences among them, which should
never be required of them in examinations. Thus, we do not encumber the text with exhaustive lists
of preparations, which properly belong in a formulary, although we hope that enough has been
mentioned to cover much routine prescribing, and many drugs have been included solely for
identification.
The role and status of a textbook. In this computer age, a textbook still plays a coveted role.
Unlike electronic search engines, a textbook allows one to browse and amble a route to the question
posed, perhaps acquiring information along the way that one had never thought existed. We aspire
to provide one such route.
A useful guide to drug use must offer clear conclusions and advice. If it is to be of reasonable
size, it may often omit alternative acceptable courses of action. What it recommends should rest on
sound evidence, where this exists, and on an assessment of the opinions of the experienced where
it does not.
Increasingly, guidelines produced by specialist societies and national and international bodies
have influenced the selection of drugs. We provide or refer to these as representing a consensus of
best practice in particular situations. Similarly, we assume that the reader possesses a formulary,
local or national, that will provide guidance on the availability, including doses, of a broad range
of drugs. Yet the practice of medicinal therapeutics by properly educated and conscientious doctors
working in settings complicated by intercurrent disease, metabolic differences or personality, involves
challenges beyond the rigid adherence to published recommendations. The role of a textbook is to
provide the satisfaction of understanding the basis for a recommended course of action and to
achieve an optimal result by informed selection and use of drugs. In this our twelfth edition, we
can but reassert our belief in this principle. The textbook is dead: long live the textbook.
2
Francis Bacon (1561–1626) Essays (1625) ‘Of studies’. Philosopher and scientist, Bacon introduced the idea of the
experimental or inductive method of reasoning for understanding nature.
viii
Contributors
Mark Abrahams MB ChB DA FRCA Trevor Baglin MA MB Ch B PhD Chrysothemis Brown MA MBBS
FFPMRCA FRCP FRCPath PhD MRCPCH
Clinical Director, Consultant Haematologist, Wellcome Trust Post-doctoral Clinical
Musculoskeletal Services, Cambridge University Hospitals NHS Research Fellow,
Cambridge University Hospitals NHS Foundation Trust, Institute of Child Health,
Foundation Trust, Cambridge University Teaching Hospitals UCL,
Cambridge, UK NHS Trust, London, UK
Chapter 18 Pain and analgesics Cambridge, UK Chapter 39 Vitamins, calcium, bone
Chapter 29 Drugs and haemostasis
Graeme Alexander MB ChB, MA, Diana C. Brown MD MSc FRCP
MD, FRCP Devinder Singh Bansi BM DM Consultant Endocrinologist,
UCL Professor, Institute for Liver and FRCP BUPA Cromwell Hospital,
Digestive Health, Royal Free Hospital Consultant Gastroenterologist, London, UK
Pond St, Hampstead, London, UK. Imperial College Healthcare NHS Trust, Chapter 35 Adrenal corticosteroids,
Chapter 34 Liver and biliary tract London, UK antagonists, corticotrophin, Chapter 37
Chapter 32 Oesophagus, stomach and Thyroid hormones, antithyroid drugs
Sani Aliyu MBBS FRCP FRCPath duodenum, Chapter 33 Intestines
Consultant in Microbiology and Simon Davies DM (Oxon) MBBS
Infectious Diseases, Paul Bentley MA, MRCP, PhD MRCPsych MSc (Epidemiol) MSc
Cambridge University Hospitals NHS Clinical Senior Lecturer and Honorary (Affective Neuroscience)
Foundation Trust, Consultant in Neurology and Stroke Associate Professor,
Cambridge, UK Medicine, Department of Psychiatry,
Chapter 15 Viral, fungal, protozoal and Imperial College, University of Toronto and Staff
helminthic infections London, UK Psychiatrist,
Chapter 21 Neurological disorders Centre for Addiction and Mental Health,
John Louis-Auguste BA MB ChB – epilepsy, Parkinson’s disease and Toronto, Canada
MRCP multiple sclerosis Chapter 20 Psychotropic drugs
Specialist Registrar in Gastroenterology,
Charing Cross Hospital, Blanca M. Bolea-Alamanac MD David A. Enoch BSc MBBS MSc
London, UK MSc (Affective Neuroscience) PhD MRCP FRCPath DTM&H
Chapter 32 Oesophagus, stomach and Assistant Professor, Consultant Medical Microbiologist,
duodenum, Chapter 33 Intestines Department of Psychiatry, Clinical Microbiology & Public Health
University of Toronto and Staff Laboratory,
Psychiatrist, National Infection Service
Centre for Addiction and Mental Health, Public Health England,
Toronto, Canada Cambridge University Hospitals NHS
Chapter 20 Psychotropic drugs Foundation Trust,
Cambridge, UK
Chapter 12 Chemotherapy of infections,
Chapter 13 Antibacterial drugs, Chapter
14 Chemotherapy of bacterial infections
ix
Contributors
Wendy N. Erber MBBS MD DPhil Charlotte Hateley MBBS MRes Michael C. Lee MBBS FRCA PhD
FRCPath FRCPA FAHMS MRCP (UK) DTM&H FFPMRCA
Pro Vice-Chancellor & Executive Dean ST3 Gastroenterology and Hepatology Consultant and University Lecturer,
and Professor of Pathology and Registrar, Department of Medicine,
Laboratory Medicine, Imperial College Healthcare NHS Trust, Division of Anaesthesia,
Faculty of Health and Medical Sciences, London, UK University of Cambridge,
University of Western Australia, Chapter 32 Oesophagus, stomach and Cambridge, UK
Perth, Australia duodenum, Chapter 33 Intestines Chapter 18 Pain and analgesics
Chapter 30 Red blood cell disorders
Stephen Haydock PhD FRCP Keith MacDonald MSc BSc (Hons)
Mark Evans MD FRCP Consultant Physician, DipRadPharmSci FRPharmS
University Lecturer, Musgrove Park Hospital, Deputy Director, Licensing Division,
University of Cambridge; Taunton, UK Medicines and Healthcare Products
Honorary Consultant Physician, Chapter 10 Poisoning, overdose, Regulatory Agency, London, UK
Wellcome Trust/MRC Institute of antidotes, Chapter 11 Drug dependence Chapter 6 Regulation of medicines
Metabolic Science,
Cambridge University Hospitals Thomas F. Hiemstra PhD FRCPE Justin C. Mason PhD FRCP
Foundation Trust, University Lecturer in Trials, Professor of Vascular Rheumatology,
Cambridge, UK University of Cambridge; Imperial College,
Chapter 36 Diabetes mellitus, insulin, Honorary Consultant Nephrologist, London, UK
oral antidiabetes agents, obesity Cambridge University Hospitals NHS Chapter 16 Drugs for inflammation and
Foundation Trust, joint disease
Mark Farrington MA MB BChir Cambridge, UK
FRCPath Chapter 27 Kidney and genitourinary Karim Meeran MD FRCP FRCPath
Consultant Medical Microbiologist, tract Professor of Endocrinology,
National Infection Service, Public Health Faculty of Medicine,
England, Ian Hudson BSc MBBS MD DCH Imperial College,
Cambridge University Hospitals NHS DipPharmMed FFPM FRCP London, UK
Foundation Trust, Chief Executive, Chapter 38 Hypothalamic, pituitary and
Cambridge, UK Medicines and Healthcare Products sex hormones
Chapter 12 Chemotherapy of infections, Regulatory Agency
Chapter 13 Antibacterial drugs, Chapter Chapter 4 Evaluation of drugs in Jerry P. Nolan FRCA FRCP FFICM
14 Chemotherapy of bacterial infections humans,Chapter 6 Regulation of FRCEM (Hon)
medicines Honorary Professor of Resuscitation
Andrew Grace MB PhD FRCP FACC Medicine,
FESC FAHA Lucinda Kennard BSc MBBS School of Clinical Sciences,
Research Group Head, MRCP (UK) AFHEA University of Bristol;
Department of Biochemistry, Specialist Registrar in Clinical Consultant in Anaesthesia & Intensive
University of Cambridge; Pharmacology & Allergy, Care Medicine,
Consultant Cardiologist, Cambridge University Hospitals NHS Royal United Hospital,
Cambridge University Health Partners, Foundation Trust, Bath, UK
Cambridge, UK Cambridge, UK Chapter 19 Anaesthesia and
Chapter 25 Cardiac arrhythmia Chapter 28 Respiratory system neuromuscular block
Thomas K. K. Ha MD FRACP FRCP Mike Laffan DM FRCP FRCPath David Nutt DM FRCP FRCPsych
Consultant Dermatologist, Professor of Haemostasis and FMedSci
Cambridge University Hospitals NHS Thrombosis, The Edmond J Safra Chair in
Foundation Trust, Centre for Haematology, Neuropsychopharmacology,
Cambridge, UK Imperial College, Imperial College,
Chapter 17 Drugs and the skin London, UK London, UK
Chapter 29 Drugs and haemostasis Chapter 20 Psychotropic drugs
x
Contributors
Sir Munir Pirmohamed MB ChB Mike Schachter MB BSc FRCP Clare Thornton PhD MRCP (Rheum)
(Hons) PhD FRCP FRCP(E) FBPhS Principal Teaching Fellow in Clinical Consultant Rheumatologist,
FMedSci Pharmacology, Homerton University Hospital,
David Weatherall Chair of Medicine and Imperial College, London, UK
NHS Chair of Pharmacogenetics, London, UK Chapter 16 Drugs for inflammation and
University of Liverpool; Chapter 1 Clinical pharmacology, joint disease
Associate Executive Pro-Vice Chancellor Chapter 2 Topics in drug therapy,
for Clinical Research, Chapter 8 General pharmacology, Patrick Vallance FRCP FMedSci FRS
University of Liverpool; Chapter 9 Unwanted effects and President Research and Development,
Director, adverse drug reactions GlaxoSmithKline,
MRC Centre for Drug Safety Science Brentford, UK
and Wolfson Centre for Personalised Surender K. Sharma MD PhD Chapter 3 Discovery and development
Medicine, Chief, of drugs
Liverpool, UK Division of Pulmonary,
Chapter 8 General pharmacology Critical Care and Sleep Medicine; Harpreet Wasan MBBS FRCP
Head, Consultant & Reader in Medical
June Raine BM BCh MSc FRCP Department of Medicine; Oncology,
Director, All India Institute of Medical Sciences, Hammersmith Hospital,
Vigilance and Risk Management of New Delhi, India Imperial College Healthcare NHS Trust,
Medicines, Chapter 14 Chemotherapy of bacterial London, UK
Medicines and Healthcare Products, infections Chapter 31 Neoplastic disease and
Regulatory Agency, immunosuppression
London, UK M. Hasib Sidiqi MBBS FRACP FRCPA
Chapter 4 Evaluation of drugs in Advance Hematology Fellow,
humans, Chapter 6 Regulation of Mayo Clinic Rochester, MN, USA;
medicines Clinical Lecturer,
University of Western Australia,
Sir Michael Rawlins GBE MD FRCP Perth, Australia
FMedSci Chapter 30 Red blood cell disorders
Chair,
Medicines and Healthcare Products Rahat Tauni BSc MBBS (Hons) MRCP
Regulatory Agency (MHRA), CertMedEd
London, UK Specialist Registrar,
Chapter 5 Health technology assessment Diabetes and Endocrinology,
Cambridge University Hospitals NHS
John P. D. Reckless DSc, MD, FRCP Foundation Trust,
Honorary Reader, Cambridge, UK
University of Bath, Chapter 36 Diabetes mellitus, insulin,
Bath, UK oral antidiabetes agents, obesity
Chapter 26 Hyperlipidaemias
xi
This page intentionally left blank
Acknowledgements
The present work reflects our wide reuse of material by those who wrote chapters for previous
editions of this book. The editors have pleasure in acknowledging their proficiency and take this
opportunity of expressing to them our grateful thanks. Those who contributed to the tenth edition
are:
Dr Nigel S Baber (Chapters 4, 5, 7, 8), Professor Sir Peter Rubin (Chapter 3), Dr Francis Hall
(Chapter 16), Dr Charles R J Singer (Chapter 30), Dr Pippa G Corrie and Dr Charles R J Singer
(Chapter 31), Dr Michael Davis (Chapters 33, 34, 35), Dr Gerard S Conway (Chapter 38).
xiii
This page intentionally left blank
Section | 1 |
General
1
1
Clinical pharmacology
Mike Schachter
2
Clinical pharmacology Chapter |1|
biological effects; that is, the exact science of specialty; indeed, no medical school can be considered
drug action, which is pharmacology. Subsequently complete without a department or sub-department of clinical
the discipline underwent a major expansion pharmacology.
resulting from technology that allowed the A signal pioneer was Harry Gold8 (1899–1972), of Cornell
understanding of molecular action and the University, USA, whose influential studies in the 1930s
capacity to exploit this. The potential showed the qualities needed to be a clinical pharmacologist.
consequences for drug therapy are enormous. All In 1952, he wrote in a seminal article:
cellular mechanisms (normal and pathological), in
their immense complexity, are, in principle, a special kind of investigator is required, one whose
identifiable. What seems almost an infinite
training has equipped him not only with the principles
number of substances, transmitters, local
and technics of laboratory pharmacology but also with
hormones, cell growth factors, can be made,
knowledge of clinical medicine …
modified and tested to provide agonists, partial
agonists, inverse agonists and antagonists. Clinical scientists of all kinds do not differ
Moreover, the unravelling of the human genome fundamentally from other biologists; they are set apart
opens the way for interference with disease only to the extent that there are special difficulties
processes in ways that were never thought and limitations, ethical and practical, in seeking
possible before now. knowledge from man.9
Increasingly large numbers of substances will
deserve to be investigated and used for altering Willingness to learn the principles of pharmacology, and
physiology to the advantage of humans. With all how to apply them in individual circumstances of infinite
these developments, and their potential for good, variety is vital to success without harm: to maximise benefit
comes capacity for harm, whether inherent in the and minimise risk. All of these issues are the concern of
substances themselves or resulting from human clinical pharmacology and are the subject of this book.
misapplication. Successful use of the power More detailed aspects comprise:
conferred (by biotechnology in particular) requires
1. Pharmacology
understanding of the growing evidence base of
the true consequences of interference. The ■Pharmacodynamics: how drugs, alone and in
temporary celebrity of new drugs is not a new combination, affect the body (young, old, well,
phenomenon. Jean Nicholas Corvisart6 (1755–1821) sick).
reputedly expressed the issue in the dictum: ‘Here ■ Pharmacokinetics: absorption, distribution,
is a new remedy; take it fast, as long as it still metabolism, excretion or how the body – well or
works’. sick – affects drugs.
2. Therapeutic evaluation
■ Whether a drug is of value.
Clinical pharmacology provides the scientific basis for: ■ How it may best be used.
• the general aspects of rational, safe and effective drug ■ Formal therapeutic trials.
therapy
• drug therapy of individual diseases
• the safe introduction of new medicines.
8
Gold H 1952 The proper study of mankind is man. American Journal
of Medicine 12:619. The title is taken from An Essay on Man by
The drug and information explosion of the past six Alexander Pope (English poet, 1688–1744), which begins with the
decades, combined with medical need, has called into being lines: ‘Know then thyself, presume not God to scan,/The proper study
of mankind is man’. Indeed, the whole passage is worth appraisal, for
a new discipline, clinical pharmacology.7 The discipline it reads as if it were relevant to modern clinical pharmacology and
finds recognition as both a health-care and an academic drug therapy.
9
Self-experimentation has always been a feature of clinical
pharmacology. A survey of 250 members of the Dutch Society of
6
He was Emperor Napoleon’s favourite physician. Clinical Pharmacology evoked 102 responders of whom 55 had carried
7
The term was first used by Paul Martini (1889–1964). He addressed out experiments on themselves (largely for convenience) (van
issues that are now integral parts of clinical trials, including the use of Everdingen J J, Cohen A F 1990 Self-experimentation by doctors.
placebo, control groups, sample size, relationship between dose and Lancet 336:1448). A spectacular example occurred at the 1983
response and probability of efficacy. His monograph Methodology of meeting of the American Urological Association at Las Vegas, USA,
Therapeutic Investigation (Springer, Berlin, 1932), was published in during a lecture on pharmacologically induced penile erection, when
German and went largely unnoticed by English speakers (Shelly J H, the lecturer stepped out from behind the lectern to demonstrate
Baur M P 1999 Paul Martini: the first clinical pharmacologist? Lancet personally the efficacy of the technique (Zorgniotti A W 1990
353:1870–1873). Self-experimentation. Lancet 36:1200).
3
Section |1| General
■ Surveillance studies for both efficacy and safety to acquire. However humane and caring doctors may be,
(adverse effects) – pharmacoepidemiology and they cannot dispense with scientific skill. Knowledge of
pharmacovigilance. clinical pharmacology underpins decisions in therapeutics,
3. Control which is concerned with the prevention, suppression or
■ Rational prescribing and formularies. cure of disease and, from the point of view of society, is
■ Official regulation of medicines. the most vital aspect of medicine.
■ Social aspects of the use and misuse of medicines. Pharmacology is the same science whether it investigates
■ Pharmacoeconomics. animals or humans. The need for it grows rapidly as not only
scientists, but now the whole community, can see its promise
Clinical pharmacology finds expression in concert with of release from distress and premature death over yet wider
other clinical specialties. Therapeutic success with drugs is fields. The concomitant dangers of drugs (fetal deformities,
becoming more and more dependent on the user having adverse reactions, dependence) only add to the need for
at least an outline understanding of both pharmacodynamics the systematic and ethical application of science to drug
and pharmacokinetics. This outline is quite simple and easy development, evaluation and use, i.e. clinical pharmacology.
Baber, N.S., Ritter, J.M., Aronson, J.K., Honig, P., 2007. The value and future of Reidenberg, M.M., 2008. A new look at
2004. Medicines regulation and clinical pharmacology. Clin. Pharma- the profession of clinical pharmacol-
clinical pharmacology. Br. J. Clin. col. Ther. 81 (1), 17–18. ogy. Clin. Pharmacol. Ther. 83 (2),
Pharmacol. 58 (6), 569–570 (and Laurence, D.R., 1989. Ethics and law in 213–217 (and other articles in this
other articles in this issue). clinical pharmacology. Br. J. Clin. issue).
Dollery, C.T., 2006. Clinical pharmacol- Pharmacol. 27, 715–722. Report. Pricewaterhouse Cooper 2016
ogy – the first 75 years and a view Rawlins, M.D., 2005. Pharmacopolitics Clinical Pharmacology and Therapeu-
of the future. Br. J. Clin. Pharmacol. and deliberative democracy. Clin. Med. tics. The case for savings in the NHS
61, 650–665. (Northfield Il) 5, 471–475. 168:1–25.
FitzGerald, G.A., 2007. Clinical pharma- Rawlins, M.D., 2015. National Waldman, S.A., Christensen, N.B., Moore,
cology or translational medicine and Institute for Clinical Excellence: NICE J.E., Terzic, A., 2007. Clinical pharma-
therapeutics: reinvent or rebrand and works. J. R. Soc. Med. 108 (6), 211– cology: the science of therapeutics.
expand? Clin. Pharmacol. Ther. 81 (1), 219. Clin. Pharmacol. Ther. 81 (1), 3–6.
19–20.
4
Chapter | 2|
5
Another random document with
no related content on Scribd:
regarded in the light of a leader, since his decision seems to have
been esteemed by them as a sort of law; and the perfect
acquiescence of even the most troublesome in the course which he
recommended, is a proof of his predominant influence. The tone and
style of the address itself, also imply that the speaker thought he had
good reason to believe that others were looking to him in particular,
for the decision which should regulate their opinions on this doubtful
question. After Simon Peter, as the great chief of the apostles, had
first expressed his opinion on the question under discussion, and
had referred to his own inspired divine revelations of the will of God
in respect to the Gentiles, Paul and Barnabas next gave a full
account of their operations, and of the signs and wonders with which
God had followed their labors.
After the full exposition made by Paul and Barnabas, of all their
conduct, James arose to make his reply in behalf of the close
adherents of Mosaic forms, and said, “Men and brethren! listen to
me. Simeon has set forth in what manner God did first condescend
to take from the heathen a people for his name. And with this, all the
words of the prophets harmonize, as it is written, ‘After these things I
will turn back, and will rebuild the fallen tabernacle of David; I will
both rebuild its ruins and erect it again, in order that the rest of
mankind may seek out the Lord, together with all the heathen who
are called by my name, saith the Lord who made all things.’ ‘Well
known to God are all his works from eternity.’ So I think that we
ought not to make trouble for those who have turned from the
heathen, to God; but that we should direct them to refrain from things
that have been offered unto idols, and from fornication, and from
what has been strangled, and from blood. For Moses has, from
ancient generations, in these cities, those who make him
known,――his law being read every sabbath day.” This opinion,
formed and delivered in a truly Christian spirit of compromise, seems
to have had the effect of a permanent decision; and the great leader
of the rigid Judaizers, having thus renounced all opposition to the
adoption of the converted heathen into full and open Christian
communion, though without the seals of the Mosaic covenant,――all
those who had originated this vexatious question, ceased their
attempts to distract the harmony of the apostles; and the united
opinions of the great apostolic chief, who had first opened the gates
of Christ’s kingdom to the heathen, and of the eminent defender of
Mosaic forms, so silenced all discussion, that thenceforth these
opinions, thus fully expressed, became the common law of the
Christian churches, throughout the world, in all ages.
This address of James (Acts xv. 13‒21.) may justly be pronounced the most obscure
passage of all that can be found in the New Testament, of equal length,――almost every
verse in it containing some point, which has been made the subject of some dispute.
Schoettgen (quoted by Bloomfield,) thus analyzes this discourse:――“It consists of three
parts;――the Exordium, (verse 13,) in which the speaker uses a form of expression
calculated to secure the good-will of his auditors;――the Statement, (verses 16‒18,)
containing also a confirmation of it from the prophets, and the reason;――the Proposition,
(verses 19‒20,) that the Gentiles are not to be compelled to Judaism, but are only to
abstain from certain things particularly offensive to the spirit of the Mosaic institutions.”
Simeon. (verse 14.) This peculiar form of Peter’s first name, has led some to suppose
that he could not be the person meant, since he is mentioned in all other narratives by the
name of Simon. Wolf imagines that Simon Zelotes must have been the person thus
distinguished, though all the difficulties are the same in his case as in Peter’s. But Simeon
(Συμεων) and Simon are the same name, the latter being only an abridged form, better
suited to the inflections of the Greek than the former.――This preference of the full Hebrew
form was doubtless meant to be characteristic of James, who seems to have been in
general very zealous for ancient Jewish usages in all things.
Has condescended to take. Common translation: “did visit them to take,” &c. This much
clearer translation is justified by the meaning which Bretschneider has given to επισκεπτομαι,
benigne voluit, &c., for which he quotes the Greek of the Alexandrian version.
Harmonize. (verse 15.) The original (συμφωνοῦσιν) refers in the same manner as this
word does to the primary idea of accordance in sound, (symphony,) and thence by a
metonymy is applied to agreement in general. The passage of prophecy is quoted by James
from Amos ix. 11, 12, and accords, in the construction which he puts upon it, much better
with the Alexandrian Greek version, than with the original Hebrew or the common
translations. The prophet (as Kuinoel observes) is describing the felicity of the golden age,
and declares that the Jews will subdue their enemies and all nations, and that all will
worship Jehovah. Now this, James accomodates to the present purpose, and applies to the
propagation of the gospel among the Gentiles, and their reception into the Christian
community. (See Rosenmueller, Acts, xv. 17, for a very full exegesis of this passage.)
Well known to God are all his works. These words have been made the subject of a
great deal of inquiry among commentators, who have found some difficulties in ascertaining
their connection with the preceding part of the discourse. Various new and unauthorized
renderings of the words have been proposed, but have been generally rejected. It seems to
me that the force of the passage is considerably illustrated by throwing the whole emphasis
of the sentence upon the word “all,”――“Known unto God are all his works from the
beginning of ages.” James is arguing on the equal and impartial grace of God, as extended
not only to the Jews, but also to the Gentiles;――not to one nation merely, but to all his
creatures. “Thus saith the Lord who makes (or does) all things.” The original Hebrew of the
prophecy indeed, does not contain this, but that is itself a circumstance which shows that
James had a particular object in this ♦ accommodation of the words to this form and
purpose.
So I think, &c. (verse 19.) Hammond and others have attempted to find in the original of
this verb (κρινω) a peculiar force, implying that James announced his decision with a kind of
judicial emphasis, in the character of “Bishop of Jerusalem.” The groundlessness of this
translation is shown by Bloomfield’s numerous references to classical authority for the
simple meaning of “think.” The difficulties in the twentieth verse are so numerous and
weighty, and have been made the subject of such protracted and minute discussions by all
the great commentators, that it would be vain to attempt any account of them here.
Bishop of Jerusalem. The first application of this title to James, that appears on record,
is in Eusebius, who quotes the still older authority of Clemens Alexandrinus. (Church
History, II. 1.) The words of Eusebius are, “Then James, who was called the brother of our
Lord, because he was the son of Joseph, and whom, on account of his eminent virtue,
those of ancient times surnamed the Just, is said to have first held the chair of the bishopric
of Jerusalem. Clemens, in the sixth book of his Institutes, distinctly confirms this. For he
says that ‘after the Saviour’s ascension, although the Lord had given to Peter, James, and
John, a rank before all the rest, yet they did not therefore contend among themselves for
the first distinction, but chose James the Just, to be bishop of Jerusalem.’ And the same
writer, in the seventh book of the same work, says these things of him, besides: ‘To James
the Just, and John, and Peter, did the Lord, after the resurrection, grant the knowledge, [the
gnosis, or knowledge of mysteries,] and these imparted it to the other disciples.’”
In judging of the combined testimony of these two ancient writers, it should be observed
that it is not by any means so ancient and direct as that of Polycrates, on the identity of
Philip the apostle, and Philip the deacon, which these very Fathers quote with assent. Nor
can their opinion be worth any more in this case than in the other. On no point, where a
knowledge of the New Testament, and a sound judgment are the only guides, can the
testimony of the Fathers be considered of any value whatever; for the most learned of them
betray a disgraceful ignorance of the Bible in their writings; nor can the most acute of them
compare, for sense and judgment, with the most ordinary of modern commentators. The
whole course of Patristic theology affords abundant instances of the very low powers of
these writers, for the discrimination of truth and falsehood. The science of historical criticism
had no existence among them――nor indeed is there any reason why they should be
considered persons of any historical authority, except so far as they can refer directly to the
original sources, and to the persons immediately concerned in the events which they
record. On all matters of less unexceptionable authority, where their testimony does not
happen to contradict known truth or common sense, all that can be said in their favor, is,
that the thing thus reported is not improbable; but all supplements to the accounts given in
the New Testament, unless they refer directly to eye-witnesses, may be pronounced very
suspicious and wholly uncertain. In this case, Eusebius’s opinion that James, the brother of
our Lord was the son of Joseph, is worth no more than that of the latest commentator;
because he had no more historical aids than the writers of these days. Nor is the story of
Clemens, that James was bishop of Jerusalem, worth any more; because he does not refer
to any historical evidence.
his epistle.
A brief review of the contents of the epistle will furnish the best
means of ascertaining its scope and immediate object, and will also
afford just ground for tracing the connection, between the design of
the apostle and the remarkable events in the history of those times,
which are recorded by the other writers of that age. He first urges
them to persevere in faith, without wavering or sinking under all the
peculiar difficulties then pressing on them; and refers them to God as
the source of that wisdom which they need for their direction. From
him alone, all good proceeds; but no sin, nor temptations to sin. The
cause of that, lies in man himself: let him not then blasphemously
ascribe his evil dispositions nor the occasions of their development,
to God; but seeking wisdom and strength from above, let him resist
the tempter:――blessed is the man that thus endures and
withstands the trial. He next points out to them the utter
worthlessness of all the distinctions of rank and wealth among those
professing the faith of Jesus. Such base respect of persons on the
score of accidental worldly advantages, is denounced, as being
foreign to the spirit of Christianity. True religion requires something
more than a profession of faith; its substance and its signs are the
energetic and constant practice of virtuous actions, and it allows no
dispensations or excuses to any one. He next dwells especially on
the high responsibilities of those who assume the office of teaching.
The tongue requires a most watchful restraint, lest passion or haste
pervert the advantages of eminence and influence, into the base
instruments of human wrath. The true manifestations of religious
knowledge and zeal, must be in a spirit of gentleness, forbearance,
and love,――not in the expressions of hatred, nor in cursing. But of
this pure, heavenly spirit, their late conduct had shown them to be
lamentably destitute. Strifes, tumults, and bitter denunciations, had
betrayed their un-Christian character. They needed therefore, to
humbly seek this meek spirit from God, and not proudly to assume
the prerogatives of judgment and condemnation, which belonged to
Him alone. His condemnation was indeed about to fall on their
country. With most peculiar ruin would it light on those now reveling
in their ill-gotten riches, and rejoicing in the vain hope of a perpetual
prosperity. But let the faithful persevere, cheered by the memory of
the bright examples of the suffering pious of other days, and by the
hope of the coming of their Lord, whose appearance in glory and
judgment, would soon crown their fervent prayers. Meanwhile,
supported by this assurance, let them continue in a virtuous course,
watching even their words, visiting the sick in charity and mercy, and
all exhorting and instructing each other in the right way.
Many teachers. In order to understand this reference, it should be noticed that the word
masters in the common translation of chap. iii. verse 1, of this epistle, is not to be taken in
the common modern sense, but in that of “religious teachers.” The original is not Κυριοι
(Kurioi,) “Lords,” “Masters,”――but διδασκαλοι (didaskaloi,) “teachers.” The translators
probably intended it only in the latter sense; for the word “Master” really has that meaning in
such connections, in good authors of that age; and even at this day, in England, the same
usage of the word is very common, though almost unknown in this country, except in
technical phrases.
his death.
The epistle was probably the last great act of his life. No record,
indeed, of any of his labors, except this living instance, exists of his
later years; but there is certain ground for supposing that his
residence in Jerusalem was characterized by a steady course of
apostolic labors, in the original sphere of action, to which the twelve
had first confined themselves for many years. When, by the special
calls of God, in providences and in revelations, one and another of
the apostles had been summoned to new and distant fields, east,
west, north and south, “preaching repentance and remission of sins,
in his name, among all nations, beginning at Jerusalem,” and
bearing witness of his works, thence, “through Judea, and Samaria,
and unto the uttermost part of the earth,” there was still needed one,
who, highly “indued with power from on high,” might remain in that
city to which all the sons of Israel, throughout the world, looked as
the fountain of religious light. There too was the scene of the first
great triumphs of the Christian faith, as well as of the chief toils, the
trials, and the death of the great founder himself. All these
circumstances rendered Jerusalem still an important post to the
apostles; and they therefore left on that station the apostle, whose
steady courage in the cause of Christ, and blameless yet jealous
conformity to the law of Moses, fitted him at once for the bold
maintenance of his Master’s commission, and for the successful
advancement of the gospel among the faithful believers of the
ancient covenant. Thus James continued at Jerusalem throughout
his life, being kept at this important station, perhaps on account of
his age, as well as for his fitness in other respects; as there is some
reason to think that he was older than those more active apostles
who assumed the foreign departments of the work. His great weight
of character, as evinced in the council of the apostles, and by the
fear which Peter showed of offending him, very naturally gives the
idea of a greater age than that of the other apostles; and this notion
is furthermore confirmed by the circumstance that the brethren of
Jesus, among whom this apostle was certainly included, are
mentioned as assuming an authority over their divine relation, and
claiming a right to control and direct his motions, which could never
have been assumed, according to the established order of Jewish
families, unless they had been older than he. It is therefore a rational
supposition, that James was one of the oldest, perhaps the oldest, of
the apostles; and at any rate he appears to have been more
advanced in life than any of those who are characterized with
sufficient distinctness to offer the means of conjecture on this point.
The account which Josephus has given, shows that the death of
James, must have happened during Paul’s imprisonment, and is
delivered in the following words:――“The emperor, being informed of
the death of Festus, sent Albinus to be prefect of Judea. But the
younger Ananus, who, as we said before, was made high priest, was
haughty in his behavior, and very ambitious. He was also of the sect
of the Sadducees, who, as we have also observed before, are above
all other Jews severe in their judicial sentences. This then being the
temper of Ananus, he, thinking he had a convenient opportunity,
because Festus was dead, and Albinus was not yet arrived, called a
council, and brought before it James, brother of Jesus, who was
called Christ, with several others, where they were accused of being
transgressors of the law, and stoned to death. But the most
moderate men of the city, who were also the most learned in the
laws, were offended at this proceeding. They sent therefore privately
to the king, and entreated him to give orders to Ananus to abstain
from such conduct in future. And some went to meet Albinus, who
was coming from Alexandria, and represented to him, that Ananus
had no right to call a council without his permission. Albinus,
approving of what they said, wrote a very severe letter to Ananus,
threatening to punish him for what he had done. And king Agrippa
took away from him the priesthood, after he had possessed it three
months, and appointed in his stead Jesus, the son of Damnaeus.”
From this account of Josephus we learn, that James,
notwithstanding he was a Christian, was so far from being an object
of hatred to the Jews, that he was rather beloved and respected. At
least his death excited very different sensations from that of the first
James; and the Sadducean high priest, at whose instigation he
suffered, was punished for his offense by the loss of his office.
This translation is taken from Marsh’s Michaelis, (Introduction, Vol. IV. pp. 287, 288.) The
original is in the Jewish Antiquities of Josephus. (XX. ix. 1.)
“James, the brother of our Lord, surnamed the Just, was holy from
his mother’s womb. He drank neither wine, nor strong drink; nor ate
any creature wherein was life. There never came a razor upon his
beard;――he anointed not himself with oil, neither did he use a bath.
To him only it was lawful to enter into the holy of holies. He wore no
woolen, but only linen garments; and entered the temple alone,
where he was seen upon his knees, supplicating for the forgiveness
of the people, till his knees became hard, and covered with a callus,
like those of a camel. On account of his eminent righteousness, he
was called the Just, and Oblias, which signifies ‘the people’s
fortress.’ Then, after describing the divisions among the people
respecting Christianity, the account states, that all the leading men
among the Scribes and Pharisees, came to James, and entreated
him to stand up on the battlements of the temple, and persuade the
people assembled at the passover, to have juster notions concerning
Jesus; and that, when thus mounted on the battlements, he cried
with a loud voice, ‘Why do ye question me about Jesus, the Son of
Man? He even sits in heaven, at the right hand of great power, and
will come in the clouds of heaven.’ With this declaration, many were
satisfied, and cried ‘Hosanna to the Son of David.’ But the
unbelieving Scribes and Pharisees, mortified at what they had done,
produced a riot; for they consulted together, and then cried out, ‘Oh!
oh! even the Just one is himself deceived.’ They went up, therefore,
and cast down the Just, and said among themselves, ‘Let us stone
James the Just.’ And they began to stone him, for he did not die with
his fall; but turning, he kneeled, saying, ‘I entreat, O Lord God the
Father, forgive them, for they know not what they do.’ And while they
were stoning him, one of the priests, of the sons of Rahab, spoken of
by Jeremiah the prophet, cried out, ‘Cease; what do ye? Justus
prays for us.’ But a certain one among them, a fuller, took a lever,
such as he had used to squeeze garments, and smote Justus on the
head. Thus he suffered martyrdom; and they buried him in that
place, and his grave-stone yet remains near the temple.”
This story is from Hegesippus, as quoted by Eusebius, to whom alone we owe its
preservation,――the works of the original author being all lost, except such fragments,
accidentally quoted by other writers. The translation I have taken from the MS. of the Rev.
Dr. Murdock, to whose research I am already so much indebted in similar instances.
The Cananite.――In respect to this name, a most absurd and unjustifiable blunder has
stood in all the common versions of it, which deserves notice. This is the representation of
the word in the form, “Canaanite,” which is a gross perversion of the original. The Greek
word is Κανανιτης, (Kananites,) a totally different word from that which is used both in the
New Testament, and in the Alexandrian version of the Old, to express the Hebrew term for
an inhabitant of Canaan. The name of the land of Canaan is always expressed by the
aspirated form, Χανααν, which in the Latin and all modern versions is very properly
expressed by “Chanaan.” In Matthew xv. 22, where the Canaanitish woman is spoken of,
the original is Χαναναια, (Chananaia,) nor is there any passage in which the name of an
inhabitant of Canaan is expressed by the form Κανανιτης, (Cananites,) with the smooth K,
and the single A. Yet the Latin ecclesiastic writers, and even the usually accurate Natalis
Alexander, express this apostle’s name as “Simon Chananaeus,” which is the word for
“Canaanite.”
The true force and derivation of the word is this. The name assumed in the language of
Palestine by the ferocious sect above mentioned, was derived from the Hebrew primitive קנא
(Qana or Kana,) and thence the name ( קנניKanani) was very fairly expressed, according to
the forms and terminations of the Greek, by Κανανιτης, (Kananites.) The Hebrew root is a
verb which means “to be zealous,” and the name derived from it of course means, “one who
is zealous,” of which the just Greek translation is the word Ζηλωτης, (Zelotes,) the very
name by which Luke represents it in this instance. (Luke vi. 15; Acts i. 13.) One of these
names is, in short, a mere translation of the other,――nor is there any way of evading this
construction, except by supposing that Luke was mistaken in supposing that Simon was
called “the Zealot,” being deceived by the resemblance of the name “Cananites” to the
Hebrew name of that sect. But no believer in the inspiration of the gospel can allow this
supposition. Equally unfounded, and inconsistent with Luke’s translation, is the notion that
the name Cananite is derived from Cana the village of Galilee, famous as the scene of
Christ’s first miracle.
The account given in the Life of Matthew shows the character of this sect, as it existed in
the last days of the Jewish state. Josephus describes them very fully in his history of the
Jewish War, (iv. 3.) Simon probably received this name, however, not from any connection
with a sect which arose long after the death of Christ, but from something in his own
character which showed a great zeal for the cause which he had espoused.
his history.
No very direct statement as to his parentage is made in the New
Testament; but one or two incidental allusions to some
circumstances connected with it, afford ground for a reasonable
conclusion on this point. In the enumeration which Matthew and
Mark give of the four brothers of Jesus, in the discourse of the
offended citizens of Nazareth, Simon is mentioned along with
James, Juda and Joses. It is worthy of notice, also, that on all the
apostolic lists, Simon the apostle is mentioned between the brothers
James and Juda; an arrangement that can not be accounted for,
except by supposing that he was also the brother of James. The
reason why Juda is distinctly specified as the brother of James, while
Simon is mentioned without reference to any such relationship, is,
doubtless, that the latter was so well known by the appellation of the
Zealot, that there was no need of specifying his relations, to
distinguish him from Simon Peter. These two circumstances,
incidentally mentioned, may be considered as justifying the
supposition, that Simon Zelotes was the same person as Simon the
brother of Jesus. In this manner, all the old writers have understood
the connection; and though such use is no authority, it is worth
mentioning that the monkish chroniclers always consider Simon
Zelotes as the brother of Juda; and they associate these two, as
wandering together in eastern countries, to preach the gospel in
Persia and Mesopotamia. Others carry him into much more
improbable wanderings. Egypt and Northern Africa, and even Britain,
are mentioned as the scenes of his apostolic labors, in the ingenious
narratives of those who undertook to supply almost every one of the
nations of the eastern continent with an apostolic patron saint. All
this is very poor consolation for the general dearth of facts in relation
to this apostle; and the searcher for historical truth will not be so well
satisfied with the tedious tales of monkish romance, as with the
decided and unquestionable assurance, that the whole history of this
apostle, from beginning to end, is perfectly unknown, and that not
one action of his life has been preserved from the darkness of an
utterly impenetrable oblivion.